TV L250 Pill - yellow oval
Pill with imprint TV L250 is Yellow, Oval and has been identified as Lapatinib Ditosylate 250 mg. It is supplied by Teva Pharmaceuticals USA, Inc.
Lapatinib is used in the treatment of Breast Cancer, Metastatic; Breast Cancer and belongs to the drug classes EGFR inhibitors, HER2 inhibitors. There is positive evidence of human fetal risk during pregnancy. Lapatinib 250 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for TV L250
Lapatinib Ditosylate
- Imprint
- TV L250
- Strength
- 250 mg
- Color
- Yellow
- Shape
- Oval (film-coated)
- Availability
- Prescription only
- Drug Class
- EGFR inhibitors, HER2 inhibitors
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Teva Pharmaceuticals USA, Inc.
- National Drug Code (NDC)
- 00480-3237
See also:
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Arimidex
Arimidex is used to treat breast cancer in postmenopausal women. Learn about side effects ...
Femara
Femara lowers estrogen levels and is used to treat breast cancer in postmenopausal women. Learn ...
Herceptin
Herceptin is used to treat patients with metastatic breast cancer. Learn about side effects ...
Ibrance
Ibrance is used to treat HR-positive, HER2-negative breast cancer in postmenopausal women or men ...
More about lapatinib
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: EGFR inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.